| abstract |
Disclosed are the use of FasL as active pharmacological component in the treatment of TH1/TH2 diseases, compositions containing FasL and one or more cytokines, specially interferon- gamma , the use of a composition according to claims 11 and 12 for the treatment of TH1/TH2 diseases, the use of autologous Cd4<+>/FasL<->/TH1 cell lines of the patient, transfected with the FasL gene sequence or with physiologically active fragments of the FasL gene sequence for the treatment of TH1/TH2 diseases. |